This will allow the design of rational combination treatments targeting ZEB1 to convert naturally resistant PDAC CAFs to a reovirus-susceptible stroma, which will allow concurrent targeting of both tumor cells and CAFs. The gene discussed is ZEB1; the disease is neoplasm.